Showing results (361-370 of 447) with videos related to
Sort By:
Pageof 45
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.The Lancet. Oncology|August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.The Lancet. Oncology|July 24, 2020
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling studyAmit Sud, Bethany Torr, Michael E Jones, et al.The New England Journal of Medicine|June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.The Journal of Pathology|November 19, 2016
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis modelsVictoria L Bridgeman, Peter B Vermeulen, Shane Foo, et al.Plos One|April 1, 2015
Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancerMarc Y R Henrion, Mark P Purdue, Ghislaine Scelo, et al.Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 TrialPaolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.European Journal of Cancer (Oxford, England : 1990)|December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring systemJames Larkin, Michael P Brown, Ana M Arance, et al.Pageof 45